*Individual results vary. In a 72-week Zepbound (tirzepatide) study of adults without diabetes, average weight loss was 15.0% (34 lbs.) for 5 mg, 19.5% (44 lbs) for 10 mg, 20.9% (48 lbs.) for 15 mg, and 3.1% (7 lbs.) for placebo. In a 72-week Zepbound (tirzepatide) study of adults with diabetes, average weight loss was 12.8% (28 lbs.) for 10 mg, 14.7% (33 lbs.) for 15 mg, and 3.2% (7 lbs.) for placebo.
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. https://pubmed.ncbi.nlm.nih.gov/35658024
The information provided on this website is not a substitute for professional medical advice. Always consult with a qualified healthcare provider for any questions about your health or treatment.
Zepbound® is a registered trademark of Eli Lilly and Company. This website is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company. All trademarks and brand names are property of their respective owners. Use of these names, logos, and brands does not imply endorsement Genesis Lifestyle Medicine. Information about Zepbound is sourced from publicly available materials and is intended for educational and informational purposes only. All rights to such content belong to the respective company.